title: Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity.
abstract: BACKGROUND
  Tauopathies, including Alzheimer's disease and frontotemporal dementia, are diseases characterized by the formation of pathological tau protein aggregates in the brain and progressive neurodegeneration. Presently no effective disease-modifying treatments exist for tauopathies.
  
  
  METHODS
  To identify drugs targeting tau neurotoxicity, we have used a Caenorhabditis elegans model of tauopathy to screen a drug library containing 1120 compounds approved for human use for the ability to suppress tau-induced behavioral effects.
  
  
  RESULTS
  One compound, the typical antipsychotic azaperone, improved the motility of tau transgenic worms, reduced levels of insoluble tau, and was protective against neurodegeneration. We found that azaperone reduces insoluble tau in a human cell culture model of tau aggregation and that other antipsychotic drugs (flupenthixol, perphenazine, and zotepine) also ameliorate the effects of tau expression in both models.
  
  
  CONCLUSIONS
  Reduction of dopamine signaling through the dopamine D2 receptor with the use of gene knockouts in Caenorhabditis elegans or RNA interference knockdown in human cell culture has similar protective effects against tau toxicity. These results suggest dopamine D2 receptor antagonism holds promise as a potential neuroprotective strategy for targeting tau aggregation and neurotoxicity.
authors.affiliation: Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.
authors.forename: Allyson V
authors.initials: AV
authors.lastname: McCormick
authors.forename: Jeanna M
authors.initials: JM
authors.lastname: Wheeler
authors.forename: Chris R
authors.initials: CR
authors.lastname: Guthrie
authors.forename: Nicole F
authors.initials: NF
authors.lastname: Liachko
authors.forename: Brian C
authors.initials: BC
authors.lastname: Kraemer
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D017173:Caenorhabditis elegans / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D009410:Nerve Degeneration / Q000235:genetics / Q000378:metabolism; D020258:Neurotoxicity Syndromes / Q000235:genetics / Q000378:metabolism*; D024801:Tauopathies / Q000235:genetics / Q000378:metabolism*; D016875:tau Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D016875:tau Proteins